We evaluated the effect of 12 months of 300-mg oral sarpogrelate hydrochloride (SH) once daily on the symptoms of Raynaud's phenomenon, respiratory failure and cardiac function in seven patients with systemic sclerosis. Arterial blood gases, pulmonary function, mean pulmonary arterial pressure, left ventricular ejection fraction (LVEF), right ventricular ejection fraction (RVEF), white blood cell count, C-reactive protein and the plasma concentrations of fibrinopeptide A, ␤-thromboglobulin, platelet factor 4 and thrombomodulin were evaluated before and 2 and 12 months after SH administration. After 2 and 12 months of SH administration, a significant decrease was found in the frequency and duration of Raynaud's phenomenon, as well as the coldness, numbness and pain of Raynaud's phenomenon. Respiratory failure, as estimated by Hugh-Jones classification, was significantly decreased, whereas the percentage carbon monoxide diffusion capacity was significantly increased. The mean pulmonary arterial pressure decreased significantly, as did plasma fibrinopeptide A, ␤-thromboglobulin and platelet factor 4. There was no significant change in LVEF after 2 or 12 months, but after 12 months of SH administration, RVEF increased significantly. In conclusion, use of SH may
INTRODUCTION
Raynaud's phenomenon is defined as a colour change of at least two phases in the fingers and toes, accompanied by pallor, cyanosis and reactive hyperaemia, in response to cold exposure or emotional upset, as determined from the history or by direct observation. 1 The condition can be the first sign of the development of collagen disease. In systemic sclerosis, for instance, Raynaud's phenomenon is the first symptom in 70% of patients. 2 No single pathophysiological mechanism adequately explains the cold-induced vasospasm causing this phenomenon. However, there is increasing evidence that the complex actions of serotonin on vascular smooth muscle and platelets play an important part in the pathogenesis of Raynaud's phenomenon. 3, 4 Accordingly, the new selective HT 2 -serotonergic receptor antagonist, sarpogrelate hydrochloride 5 (SH; Mitsubishi Chemical Co. Ltd, Tokyo, Japan) may be useful for pharmacological studies of Raynaud's phenomenon.
The present study investigated the symptoms (Raynaud's phenomenon and respiratory failure) and laboratory data before and after 12 months of oral SH administration in seven patients with systemic sclerosis.
PATIENTS AND METHODS

PATIENTS
Patients were enrolled at the Department of Cardiology and Pneumology between 1 December 1997 and 1 December 1998. A history of smoking was a criterion for exclusion.
The study was approved by an all-institute Review Board for Human Studies, and all patients gave informed consent.
EVALUATION OF RAYNAUD'S PHENOMENON AND RESPIRATORY FAILURE
The severity of Raynaud's phenomenon was determined from the following data compiled over 3 days: the mean frequency of Raynaud's phenomenon episodes; the mean duration of the episodes; and the mean frequency of cold sensation, pain and numbness during episodes. 6 The severity of respiratory failure was estimated by the Hugh-Jones classification. These clinical evaluations were performed before and after the 300-mg oral administration of SH once daily, for 2 and 12 months.
LABORATORY EVALUATION
The white blood cell (WBC) count, C-reactive protein (CRP), arterial blood gas analysis ( 7 Twodimensional echocardiography and Doppler colour imaging of the short axis (pulmonary artery level) were performed in all patients using an imaging system Hewlett-Packard Sonos 1000 or 2500 (Hewlett-Packard, Massachusetts, USA) equipped with a 2.5 MHz transducer. The mPAP was determined by the acceleration time of the pulmonary arterial wave. 8 Radionuclide ventriculograms were obtained during sinus rhythm.
The LVEF was measured using the left anterior oblique view. 9 First-pass radionuclide ventriculograms of the right ventricle were obtained with a digital gamma camera (VERTEX-PLUS; ADAC Laboratories, San Francisco, CA, USA) interfaced to a dedicated computer. The heart was imaged in the 15°right oblique projection, and the RVEF was calculated with gated first-pass methodology, in which data obtained during right ventricular transit only (usually two -six beats) are totalled according to the temporal location in the cardiac cycle, and regions of interest are manually drawn around the right ventricle at end-diastole and end-systole. 10 Readings of RVEF and LVEF were performed concurrently by two observers.
The WBC count was determined with a System 9000 haematology analyzer (Serono Diagnostika GmbH, Freiburg, Germany; reference range for adults 4000 -9000/µl).
The reference range for CRP was < 0.4 mg/dl. Enzyme immunoassay (EIA) kits (Asserachrom PF4 and Asserachrom β-TG, Dagnostica Stago, San Diego, CA, USA) were used for the quantitative determination of PF4 and β-TG. The assay range was 1 -150 ng for PF4 and 5 -300 ng β-TG/ml plasma. Other EIA kits (Asserachrom FPA, Dagnostica Stago, San Diego, CA) were used for the quantitative determination of FPA. The assay range was 0.78 -25 ng FPA/ml plasma. In addition, EIA kits (Pasena TM; Fujiyakuhin Co. Ltd, Tokyo, Japan) were used for the quantitative determination of TM; the assay range was 1 -64 ng/ml.
STATISTICAL ANALYSIS
Data are expressed as means ± SD. The Student-Newman-Keuls test was used to compare data obtained before and after oral administration of SH; P-values of less than 0.05 were regarded as significant. All statistical analyses were performed using SAS software (SAS Institute Inc., Cary, NC).
RESULTS
PATIENT DEMOGRAPHICS
Two men and five women, aged 59.0 ± 10.4 years, had systemic sclerosis diagnosed according to the American Rheumatism Association's preliminary criteria. 1 Table 1 summarizes the clinical characteristics of the subjects. In all patients, the systemic sclerosis had been stable for at least 3 years. They had all been receiving steroids (prednisolone 5 -15 mg/day) or antiplatelet agents (ticlopidine hydrochloride 100 -200 mg/day or beraprost sodium hydrochloride 40 -60 µg/day) during the 6 months before the study.
Every patient had Raynaud's phenomenon, pulmonary fibrosis on chest radiographic films and respiratory failure (grade II on the Hugh-Jones classification). 
LABORATORY DATA
The frequency of Raynaud's phenomenon decreased significantly (P < 0.05) after 2 and 12 months of SH administration, as did the duration (P < 0.01; Fig. 1 ). In addition, the coldness (P < 0.001), pain (P < 0.01) and numbness (P < 0.001) of Raynaud's phenomenon decreased significantly. Exertional dyspnoea also decreased significantly (P < 0.05). Figure 2 shows the changes in the arterial blood gas data and lung function tests after 2 and 12 months of SH administration. Arterial blood gases did not change significantly, nor did %VC and FEV 1 /FVC. The %DL CO increased significantly (P < 0.01). The mPAP values had decreased significantly after 2 and 12 months of SH administration (P < 0.05; Fig. 3 ). There was no significant change in LVEF, but the RVEF increased significantly after 12 months of treatment (P < 0.05; Fig. 4) .
In each patient, the cardiac rhythm was the same at all three evaluations, and the differences in heart rate were < 10 beats/min.
Although the WBC count and CRP did not change significantly after SH administration, the levels of plasma FPA (P < 0.05), β-TG (P < 0.05) and PF4 (P < 0.01) decreased significantly in each patient (Fig. 5) . There was no significant change in plasma TM.
DISCUSSION
The participation of serotonin in the development of Raynaud's phenomenon in patients with systemic sclerosis has been documented. 3, 4, 11 The current study showed that oral administration of SH decreased Raynaud's phenomenon, respiratory failure and right ventricular failure in patients with systemic sclerosis. The environmental temperature did not affect the results, because the mean temperatures at the beginning and end of the study were not significantly different.
The lungs are frequently affected in systemic sclerosis. Pulmonary involvement is usually characterized by restrictive disease and impaired carbon monoxide diffusing capacity. 12 The reason for the significant decrease of respiratory failure in our patients was not clear, but it could be attributable to the significant increase of %DL CO . Patients with systemic sclerosis and severe Raynaud's phenomenon exhibited the greatest fall of %DL CO , suggesting an association between peripheral and pulmonary vascular involvement.
A correlation between respiratory failure and a rapid decrease of %DL CO has been noted. 13, 14 In fact, mPAP decreased significantly after SH administration in our study. It is possible that pulmonary arterial spasm induced by Raynaud's phenomenon decreased after administration, pulmonary blood flow increased, and %DL CO increased as a consequence. Right ventricular failure after load mismatch of the right ventricle secondary to pulmonary hypertension did not improve after 2 months of SH administration. However, right ventricular function had increased after 12 months. It is possible that right ventricular failure with pulmonary hypertension in systemic sclerosis cannot be reversed easily.
Investigation of haematological and biochemical data after SH administration showed that the WBC count and CRP did not change. However, the plasma concentrations of FPA, β-TG and PF4 all decreased significantly. From these results, it appears that SH has no anti-inflammatory effect, but does have an antiplatelet effect. Platelets have high levels of β-TG and PF4 in their granules, 
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and these substances are released when platelets are activated. These chemical mediators then cause the aggregation of platelets. 1, 15 Sarpogrelate has also been reported to inhibit thrombin-induced platelet aggregation. 15, 16 The mechanism underlying the decrease of plasma FPA is not clear, but we speculate that SH has some negative feedback effect on the coagulation system. Serum TM did not change significantly, so SH does not show its antiplatelet effect by altering TM metabolism. The drug treatment decreased mPAP by inhibiting S 2 -serotonergic receptormediated pulmonary artery contraction.
In conclusion, SH therapy decreased Raynaud's phenomenon, respiratory failure and right ventricular failure in patients with systemic sclerosis. The effect on Raynaud's phenomenon was mediated through reduction in the plasma concentrations of 
FIGURE 4
Comparison of mean pulmonary arterial pressure (mPAP) before and after sarpogrelate hydrochloride (SH) administration. *P < 0.05. 
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FPA, β-TG and PF4, and prevention of platelet aggregation. The effect on respiratory failure was related to the increase of %DL CO mediated by a decrease of mPAP. Right ventricular function improved after lengthy administration of SH.
